A detailed history of Bank Of America Corp transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 402,563 shares of KURA stock, worth $7.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
402,563
Previous 480,622 16.24%
Holding current value
$7.18 Million
Previous $10.3 Million 19.15%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$17.53 - $22.98 $1.37 Million - $1.79 Million
-78,059 Reduced 16.24%
402,563 $8.29 Million
Q1 2024

May 15, 2024

SELL
$13.42 - $23.53 $3.63 Million - $6.37 Million
-270,719 Reduced 36.03%
480,622 $10.3 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $1.14 Million - $2.16 Million
-149,907 Reduced 16.63%
751,341 $10.8 Million
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $3.8 Million - $5.53 Million
395,044 Added 78.04%
901,248 $9.54 Million
Q1 2023

May 12, 2023

BUY
$10.71 - $14.6 $2.64 Million - $3.6 Million
246,516 Added 94.93%
506,204 $6.19 Million
Q4 2022

Feb 10, 2023

BUY
$11.23 - $16.9 $2,683 - $4,039
239 Added 0.09%
259,688 $3.22 Million
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $1.88 Million - $3.04 Million
156,440 Added 151.87%
259,449 $3.54 Million
Q2 2022

Aug 12, 2022

SELL
$10.71 - $18.33 $1.56 Million - $2.67 Million
-145,548 Reduced 58.56%
103,009 $1.89 Million
Q1 2022

May 16, 2022

SELL
$11.78 - $16.98 $531,749 - $766,477
-45,140 Reduced 15.37%
248,557 $4 Million
Q4 2021

Feb 08, 2022

BUY
$12.22 - $19.57 $2.6 Million - $4.16 Million
212,618 Added 262.24%
293,697 $4.11 Million
Q3 2021

Nov 15, 2021

BUY
$15.42 - $21.72 $66,938 - $94,286
4,341 Added 5.66%
81,079 $1.52 Million
Q2 2021

Sep 13, 2021

BUY
$20.85 - $29.88 $1.6 Million - $2.29 Million
76,738 New
76,738 $1.6 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $1.19B
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.